KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings
about
Clinical applications of liquid biopsies in gastrointestinal oncologyDoes KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.KRAS testing and first-line treatment among patients diagnosed with metastatic colorectal cancer using population data from ten National Program of Cancer Registries in the United States.KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and CostsPhysical activity, tumor PTGS2 expression, and survival in patients with colorectal cancerOncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer.Oncologists' attitudes toward KRAS testing: a multisite study.KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort.Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care.KRAS biomarker testing disparities in colorectal cancer patients in New Mexico.
P2860
Q28073730-6D005165-A54E-418A-82CD-0AB595A2DEE4Q33553166-17445D8A-038A-4E14-B0B9-A1007C1217B2Q33803490-E8213DC4-BBF7-4FEC-864C-38FA66B87EE2Q35234665-C2129BA8-2E31-4C40-AF2B-2082845D7B27Q35817101-C7B5585A-1CEC-47E2-AE61-316D414BFAB7Q36113105-3448B796-4F5B-4ECA-B39E-C23CCEB5B2F8Q36614650-6E5598A3-97F8-4EB3-8707-7AA646789C7FQ36926941-A5B32E49-040F-419F-A8E7-E3E6B3789543Q37316996-7E003317-AA7B-4ACC-9867-38D3A08E8581Q37374391-92737BC2-1922-4B60-A80F-65CDA29EAB5BQ37481178-AFBF514A-D3B9-420D-9267-0B7BBA14AF7CQ38136134-2AD21AF6-4CA5-4876-BAED-53C92F81FC8AQ39065326-2E31C3B2-BB3D-4C46-AD5B-6728E5160EBCQ43994049-E24F270B-A6BB-4D6B-854F-D3C036977246Q47137265-7E46076C-4B65-4698-AAB4-2DF67E054C09
P2860
KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
KRAS testing and epidermal gro ...... l cancer in community settings
@ast
KRAS testing and epidermal gro ...... l cancer in community settings
@en
type
label
KRAS testing and epidermal gro ...... l cancer in community settings
@ast
KRAS testing and epidermal gro ...... l cancer in community settings
@en
prefLabel
KRAS testing and epidermal gro ...... l cancer in community settings
@ast
KRAS testing and epidermal gro ...... l cancer in community settings
@en
P2093
P2860
P50
P1476
KRAS testing and epidermal gro ...... l cancer in community settings
@en
P2093
Adedayo A Onitilo
Andrew E Williams
Anousheh S Mirabedi
Arnold L Potosky
CERGEN study team
Deanna Cross
Gwen L Alexander
Jennifer Webster
Katrina A B Goddard
Pamala A Pawloski
P2860
P304
P356
10.1158/1055-9965.EPI-12-0545
P577
2012-11-15T00:00:00Z